دورية أكاديمية
A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors
العنوان: | A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors |
---|---|
المؤلفون: | Yamamoto, Noboru, Kuboki, Yasutoshi, Harano, Kenichi, Koyama, Takafumi, Kondo, Shunsuke, Hagiwara, Akiko, Suzuki, Noriko, Fujikawa, Ei, Toyoizumi, Kiichiro, Mukai, Mayumi, Doi, ToshihikoAff2, IDs10637024014333_cor11 |
المصدر: | Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies. 42(4):376-385 |
قاعدة البيانات: | Springer Nature Journals |
تدمد: | 01676997 15730646 |
---|---|
DOI: | 10.1007/s10637-024-01433-3 |